Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.
Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.
Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.
Geron Corporation has completed patient enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). Top-line results are anticipated in January 2023. Imetelstat, a first-in-class telomerase inhibitor, has shown promising results in Phase 2 trials, including durable transfusion independence in patients. The IMerge trial involves approximately 170 patients and aims to evaluate red blood cell transfusion independence. The company aims to address the significant medical need for alternative treatments in lower risk MDS patients.
Geron Corporation (Nasdaq: GERN) will hold a virtual investor event on November 9 at 4:00 p.m. ET. The event will address unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis, focusing on the potential of imetelstat, Geron's first-in-class telomerase inhibitor. Attendees will hear about expansion opportunities for imetelstat and can participate in a live Q&A with experts, including Dr. Swaminathan Iyer and Dr. John Mascarenhas. A webcast will be available on Geron's Investor Relations page, archived for 30 days.
Geron Corporation (Nasdaq: GERN) reported significant findings from its IMbark Phase 2 clinical trial for imetelstat, a treatment for refractory myelofibrosis (MF). Published in the Annals of Hematology, the study indicates that patients treated with imetelstat had a median overall survival (OS) of approximately 30 months, over double the 12 months for those receiving best available therapy. The ongoing IMpactMF Phase 3 trial aims to further validate these results. Imetelstat is noted for its potential to address unmet needs in patients unresponsive to JAK inhibitors.
Geron Corporation (NASDAQ: GERN) announced the granting of a non-statutory stock option for 400,000 shares of common stock to a newly hired employee. The option was awarded on
Geron Corporation (NASDAQ: GERN) announced that Dr. John A. Scarlett, its Chairman and CEO, will present at three upcoming investor conferences in September 2021. The presentations include the H.C. Wainwright 23rd Annual Global Virtual Investment Conference on September 13, R.W. Baird 2021 Virtual Global Healthcare Conference on September 14, and Cantor Virtual Global Healthcare Conference on September 30. Live webcasts of the presentations will be available through Geron's Investor Relations webpage, with archived replays for 30 days.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for 550,000 shares of its common stock to new employees as an inducement in their employment. The options were issued on August 18, 2021, at an exercise price of $1.25 per share, matching the stock's closing price on that date. The options vest over four years, with an initial vesting of 12.5% after six months. Geron is focused on developing the telomerase inhibitor, imetelstat, and is conducting two Phase 3 clinical trials in related hematologic cancers.
Geron Corporation (Nasdaq: GERN) announced updates on its IMerge Phase 3 trial in lower risk MDS and reported second quarter financial results. As of June 30, 2021, the company has $239.1 million in cash and securities, sufficient to fund operations through Q1 2023. Enrollment in the IMerge trial reached 91%, with full enrollment expected by Q4 2021, and top-line results anticipated by Q1 2023, accelerated by three months. Furthermore, Geron plans to host an investor event in November 2021 to discuss imetelstat's potential and development pipeline.
Geron Corporation (Nasdaq: GERN) will release its Q2 2021 financial results after market close on August 16, 2021. The results will be detailed in a press release available on the company’s website. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent events. Key highlights include ongoing Phase 3 clinical trials for imetelstat in hematologic malignancies. A live webcast will also be accessible on the company's site, with an archive available for 30 days.
Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 130,000 shares of its common stock to new employees, effective July 21, 2021. The exercise price is $1.33 per share, matching the closing price on the grant date. The options will vest over four years, with 12.5% vesting after six months and the remainder in equal monthly installments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and follows the 2018 Inducement Award Plan. Geron focuses on developing imetelstat, a telomerase inhibitor, in hematologic diseases with ongoing Phase 3 trials.
Geron Corporation (Nasdaq: GERN) announced the publication of data from the IMbark Phase 2 trial in the Journal of Clinical Oncology, showcasing clinical benefits of imetelstat in treating relapsed or refractory myelofibrosis (MF). Key findings include improved symptom response rates and overall survival in patients with high disease burden. The upcoming IMpactMF Phase 3 trial will further assess imetelstat's efficacy against standard therapies, targeting 320 patients. Imetelstat, a first-in-class telomerase inhibitor, has received Fast Track designation from the FDA for MF and related conditions.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
